CT Atlantic

CT Atlantic is a Swiss biotechnology company specializing in the discovery and development of human-derived monoclonal antibodies for the treatment of cancer. The company utilizes a proprietary platform to identify and clone antibodies from the B-cells of cancer patients who have demonstrated a natural, effective immune response against their tumors. This approach focuses on cancer-testis (CT) antigens, which are highly specific to tumor cells and absent in normal adult tissues, potentially offering a superior safety profile. CT Atlantic's lead candidate, CTA01, targets the NY-ESO-1 antigen and has been evaluated in clinical trials for various solid tumors. Based in the Bio-Technopark Schlieren-Zurich, the company collaborates with academic and clinical partners to advance its pipeline of immunotherapy candidates.